CROs offering Preclinical In Vitro Studies with mRNA
8 published
8 published CROs match Preclinical In Vitro Studies and mRNA.
Locations in this set include United States, China, India, Netherlands, 30 countries, and 30+ countries.
Capabilities that show up most often in this set: Biomarker Assays, Preclinical In Vivo Studies, Bioanalysis, Discovery Research, and GLP Toxicology.
Matching companies
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
Avance BiosciencesAvance Biosciences is a CRO and contract testing organization offering CGMP- and GLP-compliant analytical and bioanalytical services for drug development. Services cover preclinical and clinical studies, CMC support, CLIA testing, and assay development.
Axcelead Drug Discovery Partners, Inc.Axcelead provides integrated drug discovery research services to pharmaceutical companies, biotech ventures, and academic institutions. Founded in 2017 from Takeda's drug discovery research base, the company offers expertise across small molecules, nucleic acids, antibodies, and multiple therapeutic modalities.
CertaraCertara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
InnoSerInnoSer is a contract research organization based in the Netherlands and Belgium, supporting discovery and preclinical drug development. It offers in vivo and in vitro disease models and GLP toxicology studies.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/preclinical-in-vitro/mrna.md